↓ Skip to main content

Dove Medical Press

Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives

Overview of attention for article published in Therapeutics and Clinical Risk Management, March 2021
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (72nd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

news
1 news outlet

Citations

dimensions_citation
37 Dimensions

Readers on

mendeley
73 Mendeley
Title
Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives
Published in
Therapeutics and Clinical Risk Management, March 2021
DOI 10.2147/tcrm.s251668
Pubmed ID
Authors

Dwan-Ying Chang, Wei-Li Ma, Yen-Shen Lu

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 73 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 10%
Student > Bachelor 6 8%
Student > Postgraduate 4 5%
Student > Master 4 5%
Student > Ph. D. Student 3 4%
Other 8 11%
Unknown 41 56%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 10 14%
Medicine and Dentistry 9 12%
Agricultural and Biological Sciences 3 4%
Unspecified 2 3%
Engineering 2 3%
Other 5 7%
Unknown 42 58%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 March 2024.
All research outputs
#4,839,541
of 25,387,668 outputs
Outputs from Therapeutics and Clinical Risk Management
#230
of 1,323 outputs
Outputs of similar age
#118,021
of 451,361 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#5
of 14 outputs
Altmetric has tracked 25,387,668 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 451,361 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.